Global Dextromethorphan Market Growth (Status and Outlook) 2025-2031

According to this study, the global Dextromethorphan market size will reach US$ million by 2031.

The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and acts as a non-competitive channel blocker. It is one of the widely used antitussives, and is also used to study the involvement of glutamate receptors in neurotoxicity.

United States market for Dextromethorphan is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Dextromethorphan is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Dextromethorphan is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Dextromethorphan players cover Teva, Sanofi, Johnson & Johnson, Bayer, Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Dextromethorphan Industry Forecast” looks at past sales and reviews total world Dextromethorphan sales in 2024, providing a comprehensive analysis by region and market sector of projected Dextromethorphan sales for 2025 through 2031. With Dextromethorphan sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dextromethorphan industry.

This Insight Report provides a comprehensive analysis of the global Dextromethorphan landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Dextromethorphan portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dextromethorphan market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dextromethorphan and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dextromethorphan.

This report presents a comprehensive overview, market shares, and growth opportunities of Dextromethorphan market by product type, application, key players and key regions and countries.

Segmentation by Type:
Tablets
Syrups

Segmentation by Application:
Cold
Acute Or Chronic Bronchitis
Bronchial Asthma
Sore Throat
Tuberculosis (TB)

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva
Sanofi
Johnson & Johnson
Bayer
Bristol-Myers Squibb
GSK
IriSys R&D
TSH Biopharm
Endo International
Axsome Therapeutics
Strive Pharmaceuticals
Cellix Bio
Stada Arzneimittel
Yabo Pharmaceutical
Zhuhai Tianda Pharma
Sichuan Shenghe Pharmaceutical
Zhejiang Kangde Pharmaceutical Group
Zhejiang Anbao Pharmaceutical
Jiangsu Zhongtian Pharmaceutical

Please note: The report will take approximately 2 business days to prepare and deliver. Show more